HIV protease inhibitors (HIV-PI) have been shown to exert anti-angiogenic and anti-tumor actions independently from their antiretroviral effect. Based on these studies, HIV-seronegative patients with classic Kaposi’s sarcoma were treated with Indinavir and followed for clinical evolution, drug pharmacokinetics and KS biomarkers. A favorable clinical course was associated with high drug plasma levels, reduced production of basic fibroblast growth factor, lower numbers of circulating endothelial cell numbers, and a decrease of antibody titers against HHV8.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Data di pubblicazione: | 2009 | |
Titolo: | Clinical corse of classic Kaposi’s sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. | |
Autori: | Monini P; Sgadari C; Grosso MG; Bellino S; Di Biagio A; Toschi E; Bacigalupo I; Sabbatucci M; Cencioni G; Salvi E; Leone P; Ensoli B; the Concerted Action on Kaposi’s Sarcoma: Barillari G; Moracci G; Castelli L; Gatti G; Brambilla L; Bramati M; Ferrucci S; De Pità O; Pilla MA; Di Carlo A; Giuliani M; Cottoni F; Cuccuru MA; Calmieri S; Clerico R; Potenza C; Tirelli U; Simonelli C; Martellotta F; Strumia R; Borghi A; Del Giacco S; Moi L; Piludu G; Siriani MC; Campagna M; Sarmati L; Androni M; Bianchini G; Sheldon J; Milzer J; Schulz T | |
Rivista: | AIDS | |
Parole Chiave: | FIBROBLAST-GROWTH-FACTOR; INFLAMMATORY CYTOKINES; ENDOTHELIAL-CELLS; NUDE-MICE; LESION FORMATION; SPINDLE CELLS; TAT PROTEIN; ANGIOGENESIS; ANTIBODIES; INDUCTION | |
Abstract: | HIV protease inhibitors (HIV-PI) have been shown to exert anti-angiogenic and anti-tumor actions independently from their antiretroviral effect. Based on these studies, HIV-seronegative patients with classic Kaposi’s sarcoma were treated with Indinavir and followed for clinical evolution, drug pharmacokinetics and KS biomarkers. A favorable clinical course was associated with high drug plasma levels, reduced production of basic fibroblast growth factor, lower numbers of circulating endothelial cell numbers, and a decrease of antibody titers against HHV8. | |
Digital Object Identifier (DOI): | 10.1097/QAD.0b013e3283262a8d | |
Handle: | http://hdl.handle.net/11392/534709 | |
Appare nelle tipologie: | 03.1 Articolo su rivista |